23516-80-5

Upstream product

• 657-15-8 2,2,2-trifluoro-1-(3-nitrophenyl)ethanone 
• 434-45-7 2,2,2-Trifluoroacetophenone 

Downstream Products

• 1200496-74-7 C₁₀H₈F₃NO₂ 
• 130973-96-5 m-[3-(trifluoromethyl)-3H-1,2-diazirin-3-yl]aniline 
• 17556-38-6 1-(3-aminophenyl)-2,2,2-trifluoroethanol 
• 1200496-84-9 C₂₆H₂₇F₃N₂O₄ 
• 1200496-82-7 C₂₆H₂₅F₃N₂O₃ 
• 1200496-80-5 C₁₈H₁₉F₃N₂O 
• 1200496-78-1 C₂₀H₂₁F₃N₂O₂ 
• 1200496-76-9 C₁₈H₁₇F₃N₂O₂ 
• 236386-29-1 ethyl 2-(3-trifluoroacetyltosyloximephenyl)hydrazinecarboxylate 
• 236386-31-5 ethyl 2-(3-trifluoromethyldiaziridinylphenyl)hydrazine carboxylate 
• 236386-27-9 ethyl 2-(3-trifluoroacetyloximephenyl)hydrazinecarboxylate 
• 236386-25-7 ethyl 2-(3-trifluoroacetylphenyl)hydrazinecarboxylate 
• 326897-98-7 2,2,2-trifluoro-1-(3-hydroxyphenyl)ethan-1-one 

Relevant academic research and scientific papers

An improved synthesis of 3-[3-(trifluoromethyl)-3H-1,2-diazirin-3-yl]aniline: A key intermediate in the synthesis of photoaffinity probes

An improved synthesis of 3-[3-(trifluoromethyl)-3H-1,2-diazirin-3-yl]aniline, achieving an overall yield of 38% over seven steps is reported. Only three chromatographic separations were needed and the preparation of ～0.7?g of the target compound was demon

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases

SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ?-SECRETASE-INHIBITING ACTIVITY

The following compound is provided as an agent for treating a disease induced by production, secretion and/or deposition of amyloid β protein, for example,. a compound represented by the formula (I): wherein ruing A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group, R1 is optionally substituted lower alkyl or the like, R2a and R2b are each independently hydrogen, optionally substituted lower alkyl or the like, R3a and R3c are each independently hydrogen, halogen, hydroxy, optionally substituted lower alkyl or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

BACE1 inhibitors: Optimization by replacing the P1′ residue with non-acidic moiety

Recently, we reported potent BACE1 inhibitors KMI-429, -684, and -574 possessing a hydroxymethylcarbonyl isostere as a substrate transition-state mimic. These inhibitors showed potent inhibitory activities in enzymatic and cell assays, especially, KMI-429 was confirmed to significantly inhibit Aβ production in vivo. However, acidic moieties at the P4 and P1′ positions of KMI-compounds were thought to be unfavorable for membrane permeability across the blood-brain barrier. Herein, we replaced acidic moieties at the P4 position with other hydrogen bond acceptor groups, and these inhibitors exhibited improved BACE1 inhibitory activities in cultured cells. In this study, we replaced the acidic moieties at the P1′ position with non-acidic and low molecular sized moieties.